About PolyPeptide
Located at 7 Rue de Boulogne in Strasbourg, Polypeptide operates a leading pharmaceutical manufacturing facility in France’s Grand Est region. With over 1,000 peptides produced in GMP quality, this CDMO provides:
- Development of peptide and oligonucleotide-based therapies
- Manufacturing of active pharmaceutical ingredients
- Contract development services for biotech and pharma
- Production of treatments for metabolic, cancer and cardiovascular conditions
Part of a global network with facilities across Europe, US and India, Polypeptide’s Strasbourg site contributes to the company’s expanding solid-phase peptide synthesis capabilities.
Frequently asked questions
Polypeptide delivers pharmaceutical manufacturing services in these areas:
- Active Pharmaceutical Ingredients (API)
- Peptide-based therapies
- Oligonucleotide-based therapies
- Generic APIs
- Contract Development Services
- Drug development support
- Process optimization
- Analytical method development
- Manufacturing Solutions
- GMP production
- Solid-phase peptide synthesis (SPPS)
- Scale-up services
The company operates under GMP standards for pharmaceutical production.
Polypeptide’s operations include these manufacturing capabilities:
| Category | Details |
|---|---|
| Production Track Record |
|
| Technical Capabilities |
|
| Treatment Areas |
|
Polypeptide maintains manufacturing and development facilities across three continents:
- Europe
- Malmö facility – SPPS production
- Braine-l’Alleud site – Large-scale manufacturing
- United States
- API manufacturing facility
- Development laboratories
- India
- Production facility
- Research center
The company employs 1,273 staff members across these locations as of 2023.
More details about PolyPeptide
A leading biotech company in Strasbourg
Polypeptide, established in 1952, operates as a cosmetic lab and pharmaceutical manufacturing facility from its location at 7 Rue de Boulogne, Strasbourg. The company has grown to become a significant player in the Grand Est region’s biotech sector.
Specialized manufacturing and development services
As a Contract Development & Manufacturing Organization (CDMO), Polypeptide focuses on peptide synthesis and oligonucleotide-based therapies. The company has successfully manufactured over 1,000 peptides meeting GMP quality standards.
Core service offerings
- Development of active pharmaceutical ingredients (API)
- Manufacturing of proprietary and generic compounds
- Solid phase peptide synthesis (SPPS)
- Oligonucleotides API production
Global presence and local expertise
While headquartered in Strasbourg, France, Polypeptide maintains facilities across Europe, the United States, and India. The company employs 1,273 professionals who contribute to its drug development and manufacturing operations.
Production capabilities and expansion
The company is actively expanding its manufacturing capacity, with plans to double its solid-phase peptide production. This growth includes new large-scale SPPS facilities, reinforcing its position in pharmaceutical ingredient manufacturing.
Treatment applications
Polypeptide’s products support treatments for:
- Metabolic diseases
- Cancer therapies
- Cardiovascular disorders
Recent developments
In 2021, Polypeptide enhanced its service portfolio by adding oligonucleotides API manufacturing to its capabilities, strengthening its position in the biotech industry.
Company gallery
